We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Auna S.A. (AUNA) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Auna S.A. (AUNA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Auna S.A. is one of 1012 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Auna S.A. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AUNA's full-year earnings has moved 8.3% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, AUNA has moved about 25.8% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 6.9% on a year-to-date basis. As we can see, Auna S.A. is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is BioMarin Pharmaceutical (BMRN - Free Report) . The stock has returned 8.3% year-to-date.
In BioMarin Pharmaceutical's case, the consensus EPS estimate for the current year increased 10.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Auna S.A. belongs to the Medical Services industry, which includes 59 individual stocks and currently sits at #83 in the Zacks Industry Rank. On average, stocks in this group have gained 4.1% this year, meaning that AUNA is performing better in terms of year-to-date returns.
BioMarin Pharmaceutical, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 510-stock industry is ranked #70. The industry has moved +7.1% so far this year.
Auna S.A. and BioMarin Pharmaceutical could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Auna S.A. (AUNA) Stock Outpacing Its Medical Peers This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Auna S.A. (AUNA - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Auna S.A. is one of 1012 companies in the Medical group. The Medical group currently sits at #4 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Auna S.A. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AUNA's full-year earnings has moved 8.3% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, AUNA has moved about 25.8% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 6.9% on a year-to-date basis. As we can see, Auna S.A. is performing better than its sector in the calendar year.
Another Medical stock, which has outperformed the sector so far this year, is BioMarin Pharmaceutical (BMRN - Free Report) . The stock has returned 8.3% year-to-date.
In BioMarin Pharmaceutical's case, the consensus EPS estimate for the current year increased 10.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Auna S.A. belongs to the Medical Services industry, which includes 59 individual stocks and currently sits at #83 in the Zacks Industry Rank. On average, stocks in this group have gained 4.1% this year, meaning that AUNA is performing better in terms of year-to-date returns.
BioMarin Pharmaceutical, however, belongs to the Medical - Biomedical and Genetics industry. Currently, this 510-stock industry is ranked #70. The industry has moved +7.1% so far this year.
Auna S.A. and BioMarin Pharmaceutical could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.